Ticker brief
SPRY
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
6
authors 14d
6
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-06-24 → 2026-06-26 · now -0.40 (−1 bearish … +1 bullish)
Who spoke6
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @CrweWorld | C | · | 1 | +0.05 |
| @Quantumup1 | C | -1.95 | 1 | +0.20 |
| @OpenOutcrier | C | · | 1 | -0.45 |
| @BPharmCatalyst | C | · | 1 | -0.45 |
| @ABBONews | C | · | 1 | +0.20 |
| @BiotechCH | B | -1.16 | 1 | -0.40 |
Recent signals6of 6 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-06-26 | @BiotechCH | -0.40 | CVS Caremark deferred adding SPRY's Neffy to formulary until January 2027. | · | tweet ↗ |
| 2026-06-25 | @ABBONews | +0.20 | Cantor reiterated Overweight and $30 PT after formulary delay disclosure. | · | tweet ↗ |
| 2026-06-25 | @BPharmCatalyst | -0.45 | SPRY says Neffy failed to secure commercial insurance coverage and lowered FY 2026 opex guidance. | · | tweet ↗ |
| 2026-06-25 | @OpenOutcrier | -0.45 | ARS Pharmaceuticals cuts 2026 expenses after no new neffy coverage gains; down premarket. | · | tweet ↗ |
| 2026-06-25 | @Quantumup1 | +0.20 | Cantor reiterated SPRY Overweight with $30 despite PBM formulary delay. | · | tweet ↗ |
| 2026-06-24 | @CrweWorld | +0.05 | ARS Pharmaceuticals provides commercial and financial updates. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.